- Extended-release and long-acting opioid medications. // WHO Drug Information;2012, Vol. 26 Issue 3, p265
The article reports on a 2012 decision which the U.S. Food and Drug Administration made to approve a risk evaluation and mitigation strategy for extended-release and long-acting opioids.
- Risk Evaluation and Mitigation Strategies for Older Adults with Persistent Pain. Arnstein, Paul; Herr, Keela // Journal of Gerontological Nursing;Apr2013, Vol. 39 Issue 4, p56
The U.S. Food and Drug Administration issued Risk Evaluation and Mitigation Strategies for certain analgesic agents, but all medicines for older adults warrant risk-reduction considerations. Although not all older adults have pain, a higher prevalence of persistent pain exists in this...
- US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids. Mercadante, Sebastiano; Craig, David; Giarratano, Antonello // Drugs;2012, Vol. 72 Issue 18, p2327
Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks...
- New Drugs of 2012, Part 1. CHIU, TIMOTHY; DAY, JENNIFER; TORRES, NINA ESCASA; HO, HENRY; LOUCKS, AIMEE; MATSUNAGA, ZIPPORAH; MONROE, DOUG; POWERS, DANIEL; RICHMOND, CATHLENE; SHIN, PATRICK; YAMADA, BRIAN // California Journal of Health-System Pharmacy;Jan/Feb2013, Vol. 25 Issue 1, p7
The article evaluates various medications including the Dymista nasal spray, Qnasl beclomethasone dipropionate nasal aerosol, and Sklice Ivermectin lotion.
- Drug Labeling Seminar Provides Industry Updates. // Townsend Letter for Doctors & Patients;May2004, Issue 250, p18
Presents information on the seminar sponsored by the American Association of Homeopathic Pharmacists in Washington, D.C. in September 2003. Focus of seminars on drug labeling requirements and the Food and Drug Administration and Federal Trade Commission's scrutiny of product label claims;...
- Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose? Bannwarth, Bernard // Drugs;2012, Vol. 72 Issue 13, p1713
During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already...
- Appointments. // American Journal of Health-System Pharmacy;4/15/2013, Vol. 70 Issue 8, p650
The article announces the appointments of pharmacists Amir Emamifar and Richard Artymowicz to serve on the Continuing Pharmacy Education Commission of the Accreditation Council for Pharmacy Education.
- Proposal to improve MedWatch: Decentralized, regional surveillance of adverse drug reactions. Motl, Susannah; Timpe, Erin; Eichner, Samantha // American Journal of Health-System Pharmacy;9/1/2004, Vol. 61 Issue 17, p1840
Recommends improvements to MedWatch, the safety information and adverse-event reporting program of the United States Food and Drug Administration. Regional surveillance of adverse drug reactions (ADR); Need for pharmacists to be vigilant in detecting and reporting suspected ADR; Continuing...
- FDA Remodels REMS for Opioid Medications. Stone, Alec // ONS Connect;Sep2012, Vol. 27 Issue 9, p18
The article offers information on the remodeling of the risk evaluation and mitigation strategy (REMS) by the U.S. Food and Drug Administration (FDA).